,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,880,2,1,,26751989,5253,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
1,880,2,1,,26751989,5253,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
2,1030,2,1,,26751989,5253,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
3,1195,1,2,,48416548,5253,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
4,1332,1,1,,49699392,5253,Inactive,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
5,1457,1,1,,26751989,5253,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
6,1458,1,1,,26751989,5253,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
7,1460,1,3,,26751989,5253,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
8,1463,1,1,,26751989,5253,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
9,1468,1,1,,26751989,5253,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
10,1469,1,1,,26751989,5253,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
11,1471,2,1,,26751989,5253,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
12,1477,1,1,,26751989,5253,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
13,1479,1,2,,26751989,5253,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
14,1487,1,1,,26751989,5253,Inconclusive,27436948.0,4000.0,0.0035,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
15,1490,2,1,,26751989,5253,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
16,1688,1,1,,26751989,5253,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
17,1766,1,1,,26751989,5253,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
18,1766,1,1,,26751989,5253,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
19,1768,1,1,,26751989,5253,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
20,1768,1,1,,26751989,5253,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
21,1865,1,1,,26751989,5253,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
22,2062,1,2,,85220240,5253,Active,,,,,Ligands of bioamine (Class A) GPCRs,Other,,
23,2101,1,1,,26751989,5253,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
24,2107,1,1,,26751989,5253,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
25,2112,1,1,,26751989,5253,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
26,2240,1,1,,85788914,5253,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
27,2241,1,1,,85788914,5253,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
28,2275,1,1,,85788914,5253,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
29,2313,1,1,,85788914,5253,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
30,2322,1,1,,85788914,5253,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
31,2330,1,1,,85788914,5253,Inactive,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
32,2517,2,1,,26751989,5253,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
33,2528,1,2,,26751989,5253,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
34,2546,1,1,,26751989,5253,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
35,2549,1,1,,26751989,5253,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
36,2551,1,1,,26751989,5253,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
37,2660,1,1,,90341280,5253,Inactive,4826730.0,2475.0,,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
38,2666,1,1,,90341280,5253,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
39,2667,1,1,,90341280,5253,Inactive,4826730.0,2475.0,,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
40,2668,1,1,,90341280,5253,Inactive,4826730.0,2475.0,,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
41,7783,3,4,,103168744,5253,Unspecified,,,,,Unbound fraction (plasma),Other,14971904.0,
42,8002,5,2,,103168744,5253,Unspecified,,,,,Observed volume of distribution,Other,14971904.0,
43,19424,3,4,,103168744,5253,Unspecified,,,,,Partition coefficient (logD7.4),Other,11448232.0,
44,22627,4,3,,103168744,5253,Unspecified,,,,,Maximum rate of depolarization of the upstroke of the action potential,Other,1542097.0,
45,26362,4,3,,103168744,5253,Unspecified,,,,,Ionization constant (pKa),Other,14971904.0,
46,40537,3,7,,103168744,5253,Active,,,,,Selectivity for beta-1 adrenergic receptor,Other,2903243.0,
47,40686,3,7,,103168744,5253,Unspecified,,,,,Affinity for cow beta-2 adrenergic receptor by measuring displacement (-)-[3H]dihydroalprenolol (DHA),Other,2993621.0,
48,40694,10,1,,103168744,5253,Active,,,0.58,Kd,Affinity for cow beta-2 adrenergic receptor by measuring displacement (-)-[3H]dihydroalprenolol (DHA),Confirmatory,2993621.0,
49,40701,10,5,,103168744,5253,Active,1703760.0,403910.0,5.0,IC50,"Binding affinity towards Beta-2 adrenergic receptor by displacing [3H]dihydroalprenolol, in partially purified membrane fractions from canine lung tissue in the presence of 0.1 uM metoprolol",Confirmatory,1347318.0,
50,40702,10,5,,103168744,5253,Active,1703760.0,403910.0,5.0,IC50,In vitro Beta-2 adrenergic receptor affinity in partially purified membrane fractions from canine lung tissue using [SH]dihydroalprenolol (4.5 nM),Confirmatory,2319556.0,
51,40703,10,5,,103168744,5253,Active,1703760.0,403910.0,5.2,IC50,Tested for Beta-2 adrenergic receptor selectivity in canine lung tissue in anesthetized dogs,Confirmatory,1976812.0,
52,41153,9,2,,103168744,5253,Active,,,7.2,IC50,"Tested for Beta adrenergic receptor binding inhibition from canine ventricular tissue, using [3H]dihydroalprenolol as the radioligand in anesthetized dogs",Confirmatory,1976812.0,
53,41488,3,7,,103168744,5253,Active,,,,,Selectivity for beta-2 adrenergic receptor,Other,2903243.0,
54,41890,3,6,,103168744,5253,Active,,,,,Tested for intrinsic sympathomimetic activity (ISA); Pure antagonist,Other,2903243.0,
55,41895,3,7,,103168744,5253,Unspecified,,,,,Beta-blocking activity was measured by applying the stepwise linear discriminate analysis; Active,Other,,
56,42027,9,1,,103168744,5253,Active,,,9.0,IC50,"Binding affinity for Beta-1 adrenergic receptor by displacing [3H]dihydroalprenolol, in partially purified membrane fractions from canine ventricular muscle in the presence of 1 uM zinterol",Confirmatory,1347318.0,
57,42030,9,1,,103168744,5253,Active,,,9.0,IC50,In vitro Beta-1 adrenergic receptor affinity in partially purified membrane fractions from canine cardiac tissue using [SH]dihydroalprenolol (4.5 nM),Confirmatory,2319556.0,
58,42031,9,2,,103168744,5253,Active,,,8.9,IC50,Tested for Beta-1 adrenergic receptor selectivity in canine cardiac tissue in anesthetized dogs,Confirmatory,1976812.0,
59,47945,6,4,,103168744,5253,Unspecified,,,,,Beta-adrenoceptor blocking potency in cat as dose causing 50% inhibition of the tachycardia produced by 0.2 ug/kg iv of isoproterenol,Other,6102152.0,
60,48538,3,3,,103168744,5253,Unspecified,,,,,Percentage inhibition of depressor response in cat was determined,Other,6102152.0,
61,48982,7,1,,103168744,5253,Active,,,,,Concentration necessary to prolong APD at 95% repolarization by 20% from control.,Other,1347318.0,
62,48984,3,3,,103168744,5253,Unspecified,,,,,Percent change in force of contraction from control at a 10 uM concentration of compound (contractile function),Other,1347318.0,
63,55754,7,1,,103168744,5253,Active,,,,,Concentration required for 20% increase in action potential duration of canine Purkinje fiber (intracellular electrophysiology) in vitro measured at 95% repolarization was reported. Range is between 9-63,Other,3572962.0,
64,55773,7,1,,103168744,5253,Unspecified,,,,,Concentration required for 20% increase in the functional refractory period of canine ventricular muscle (extracellular electrophysiology) in vitro was reported. Range is between 9-4000,Other,3572962.0,
65,55901,7,1,,103168744,5253,Active,,,,,In vitro electrophysiological activity in isolated canine cardiac Purkinje fibers using standard microelectrode technique,Other,2319556.0,
66,55919,3,3,,103168744,5253,Unspecified,,,,,In vivo cardiac output in anesthetized dog at 30 mg/kg,Other,2319556.0,
67,56099,3,3,,103168744,5253,Unspecified,,,,,Compound was evaluated for Cardiac output in dog,Other,1347318.0,
68,56508,3,5,,103168744,5253,Unspecified,,,,,"Atrial conduction time by the compound in open chest anesthetized dog, after iv administration at a dose of 10.0 mg/kg.",Other,1956040.0,
69,56509,3,5,,103168744,5253,Unspecified,,,,,"Atrial conduction time by the compound in open chest anesthetized dog, after iv administration at a dose of 2.5 mg/kg.",Other,1956040.0,
70,56510,3,5,,103168744,5253,Unspecified,,,,,"Atrial conduction time by the compound in open chest anesthetized dog, after iv administration at a dose of 5.0 mg/kg.",Other,1956040.0,
71,56530,3,5,,103168744,5253,Unspecified,,,,,"Atrial effective refractory period by the compound in open chest anesthetized dog, after iv administration at a dose of 10.0 mg/kg.",Other,1956040.0,
72,56531,3,5,,103168744,5253,Unspecified,,,,,"Atrial effective refractory period by the compound in open chest anesthetized dog, after iv administration at a dose of 2.5 mg/kg.",Other,1956040.0,
73,56532,3,5,,103168744,5253,Unspecified,,,,,"Atrial effective refractory period by the compound in open chest anesthetized dog, after iv administration at a dose of 5.0 mg/kg.",Other,1956040.0,
74,56678,3,5,,103168744,5253,Unspecified,,,,,"repolarization to reach -60mV, in canine Purkinje Fibers at a concentration of 300 uM at 1000 ms (simulating normal heart rate)",Other,1956040.0,
75,56679,3,5,,103168744,5253,Unspecified,,,,,"repolarization to reach -60mV, in canine Purkinje Fibers at a concentration of 30 uM at 1000 ms (simulating normal heart rate)",Other,1956040.0,
76,56687,3,5,,103168744,5253,Unspecified,,,,,"Repolarization to reach -60mV, in canine Purkinje Fibers at a concentration of 300 uM at 300 ms (simulating tachycardia)",Other,1956040.0,
77,56688,3,5,,103168744,5253,Unspecified,,,,,"Repolarization to reach -60mV, in canine Purkinje Fibers at a concentration of 30 uM at 300 ms (simulating tachycardia)",Other,1956040.0,
78,56689,3,4,,103168744,5253,Unspecified,,,,,"Effect on the transmembrane potential of dog Purkinje fibers paced at a basic cycle length of stimulation of 1000 ms, repolarization time to -60 mV",Other,1542097.0,
79,56693,3,4,,103168744,5253,Unspecified,,,,,"Effect on the transmembrane potential of dog Purkinje fibers paced at a basic cycle length of stimulation of 1000 ms, repolarization time to -60 mV, at a concentration of 0.3 uM",Other,1542097.0,
80,56695,3,4,,103168744,5253,Unspecified,,,,,"Effect on the transmembrane potential of dog Purkinje fibers paced at a basic cycle length of stimulation of 300 ms, repolarization time to -60 mV",Other,1542097.0,
81,56698,3,4,,103168744,5253,Unspecified,,,,,"Effect on the transmembrane potential of dog Purkinje fibers paced at a basic cycle length of stimulation of 300 ms, repolarization time to -60 mV, at a concentration of 0.3 uM",Other,1542097.0,
82,56837,3,3,,103168744,5253,Unspecified,,,,,The percentage change of the duration of action potential at 75% repolarization was measured before and after the administration at 1.0 ug/mL,Other,1527781.0,
83,56838,3,3,,103168744,5253,Unspecified,,,,,Percentage change of the duration of action potential at 75% repolarization was measured before and after the administration at 10.0 ug/mL,Other,1527781.0,
84,56839,3,3,,103168744,5253,Unspecified,,,,,The percentage change of the duration of action potential at 75% repolarization was measured before and after the administration at 3.0 ug/mL,Other,1527781.0,
85,58009,3,4,,103168744,5253,Unspecified,,,,,The compound was evaluated for the change in blood pressure at MED for 0.1-30 dose range in PES model,Other,3681900.0,
86,58012,3,4,,103168744,5253,Unspecified,,,,,The compound was evaluated the change in blood pressure at 10 mg/kg active dose,Other,3681900.0,
87,58323,3,3,,103168744,5253,Unspecified,,,,,Compound was evaluated for change in Heart rate in dog,Other,1347318.0,
88,58466,3,4,,103168744,5253,Unspecified,,,,,"Heart beat by the compound in open chest anesthetized dog, after iv administration at a dose of 10.0 mg/kg.",Other,1956040.0,
89,58467,3,4,,103168744,5253,Unspecified,,,,,"Heart beat by the compound in open chest anesthetized dog, after iv administration at a dose of 2.5 mg/kg.",Other,1956040.0,
90,58468,3,4,,103168744,5253,Unspecified,,,,,"Heart beat by the compound in open chest anesthetized dog, after iv administration at a dose of 5.0 mg/kg.",Other,1956040.0,
91,58528,3,3,,103168744,5253,Unspecified,,,,,Peak range of change in left ventricular pressure in dog,Other,1347318.0,
92,58533,3,3,,103168744,5253,Unspecified,,,,,Percent change in rate of left ventricular pressure after intravenous administration of 0.3 mg/kg in Anesthetized Dogs,Other,2308138.0,
93,58534,3,3,,103168744,5253,Unspecified,,,,,Percent change in rate of left ventricular pressure after intravenous administration of 1 mg/kg in Anesthetized Dogs,Other,2308138.0,
94,58535,3,3,,103168744,5253,Unspecified,,,,,Percent change in rate of left ventricular pressure after intravenous administration of 3 mg/kg in Anesthetized Dogs,Other,2308138.0,
95,58536,3,3,,103168744,5253,Unspecified,,,,,In vivo left ventricular contractility change in anesthetized dog at 30 mg/kg,Other,2319556.0,
96,58649,3,4,,103168744,5253,Unspecified,,,,,In vivo heart rate in anesthetized dog at 30 mg/kg,Other,2319556.0,
97,58684,3,4,,103168744,5253,Unspecified,,,,,The compound was evaluated for the change in heart rate at MED for 0.1-30 dose range in PES model,Other,3681900.0,
98,58807,3,4,,103168744,5253,Unspecified,,,,,The compound was evaluated the change in heart rate at 10 mg/kg active dose,Other,3681900.0,
99,58815,3,4,,103168744,5253,Unspecified,,,,,Percent change in Heart rate after intravenous administration of 0.3 mg/kg in Anesthetized Dogs,Other,2308138.0,
100,58816,3,4,,103168744,5253,Unspecified,,,,,Percent change in Heart rate after intravenous administration of 1 mg/kg in Anesthetized Dogs,Other,2308138.0,
101,58817,3,4,,103168744,5253,Unspecified,,,,,Percent change in Heart rate after intravenous administration of 3 mg/kg in Anesthetized Dogs,Other,2308138.0,
102,59023,3,3,,103168744,5253,Unspecified,,,,,Compound was evaluated for Mean arterial pressure in dog,Other,1347318.0,
103,59026,3,3,,103168744,5253,Unspecified,,,,,In vivo mean arterial pressure in anesthetized dog at 30 mg/kg,Other,2319556.0,
104,59099,3,4,,103168744,5253,Unspecified,,,,,"Effect on atrial conduction time, after intravenous administration in open-chest anesthetized dogs at dose of 2.5 mg/kg",Other,1542097.0,
105,59100,3,4,,103168744,5253,Unspecified,,,,,"Effect on atrial conduction time, after intravenous administration in open-chest anesthetized dogs at dose of 5.0 mg/kg",Other,1542097.0,
106,59220,3,5,,103168744,5253,Unspecified,,,,,"Mean arterial pressure by the compound in open chest anesthetized dog, after iv administration at a dose of 10.0 mg/kg.",Other,1956040.0,
107,59221,3,5,,103168744,5253,Unspecified,,,,,"Mean arterial pressure by the compound in open chest anesthetized dog, after iv administration at a dose of 2.5 mg/kg.",Other,1956040.0,
108,59222,3,5,,103168744,5253,Unspecified,,,,,"Mean arterial pressure by the compound in open chest anesthetized dog, after iv administration at a dose of 5.0 mg/kg.",Other,1956040.0,
109,59244,3,4,,103168744,5253,Unspecified,,,,,"Effect on atrial effective refractory period, after intravenous administration in open-chest anesthetized dogs at dose of 2.5 mg/kg",Other,1542097.0,
110,59245,3,4,,103168744,5253,Unspecified,,,,,"Effect on atrial effective refractory period, after intravenous administration in open-chest anesthetized dogs at dose of 5.0 mg/kg",Other,1542097.0,
111,59250,3,4,,103168744,5253,Unspecified,,,,,"Effect on heart rate, after intravenous administration in open-chest anesthetized dogs at dose of 2.5 mg/kg",Other,1542097.0,
112,59251,3,4,,103168744,5253,Unspecified,,,,,"Effect on heart rate, after intravenous administration in open-chest anesthetized dogs at dose of 5.0 mg/kg",Other,1542097.0,
113,59256,3,3,,103168744,5253,Unspecified,,,,,"Effect on mean arterial pressure, after intravenous administration in open-chest anesthetized dogs at dose of 2.5 mg/kg",Other,1542097.0,
114,59257,3,3,,103168744,5253,Unspecified,,,,,"Effect on mean arterial pressure, after intravenous administration in open-chest anesthetized dogs at dose of 5.0 mg/kg",Other,1542097.0,
115,59264,3,3,,103168744,5253,Unspecified,,,,,"Effect on ventricular conduction time, after intravenous administration in open-chest anesthetized dogs at dose of 2.5 mg/kg",Other,1542097.0,
116,59265,3,3,,103168744,5253,Unspecified,,,,,"Effect on ventricular conduction time, after intravenous administration in open-chest anesthetized dogs at dose of 5.0 mg/kg",Other,1542097.0,
117,59270,3,3,,103168744,5253,Unspecified,,,,,"Effect on ventricular effective refractory period, after intravenous administration in open-chest anesthetized dogs at dose of 2.5 mg/kg",Other,1542097.0,
118,59271,3,3,,103168744,5253,Unspecified,,,,,"Effect on ventricular effective refractory period, after intravenous administration in open-chest anesthetized dogs at dose of 5.0 mg/kg",Other,1542097.0,
119,59389,3,3,,103168744,5253,Unspecified,,,,,In vivo PES efficacy in conscious dogs (iv),Other,2319556.0,
120,59402,3,4,,103168744,5253,Unspecified,,,,,The compound was evaluated for the mean effective dose for antiarrhythmic efficacy in PES model,Other,3681900.0,
121,60101,3,3,,103168744,5253,Unspecified,,,,,In vivo PES efficacy in 9 conscious dogs (PES programmed electrical stimulation protocol),Other,2319556.0,
122,60104,3,3,,103168744,5253,Unspecified,,,,,In vivo efficacy against halothane/epinephrine induced arrhythmias in 4 anesthetized dogs at 1 mg/kg,Other,2319556.0,
123,60106,3,3,,103168744,5253,Unspecified,,,,,In vivo efficacy against halothane/epinephrine induced arrhythmias in 6 anesthetized dogs at 3 mg/kg,Other,2319556.0,
124,60250,3,4,,103168744,5253,Unspecified,,,,,Number of active animals / number of tested animals in programmed electrical stimulation model (PES),Other,1347318.0,
125,60254,3,3,,103168744,5253,Unspecified,,,,,number of effected animals / number of tested animals at 3 mg/kg in a halothane / epinephrine model,Other,1347318.0,
126,60317,3,3,,103168744,5253,Unspecified,,,,,Percent change in Effective refractory period after intravenous administration of 0.3 mg/kg in Anesthetized Dogs,Other,2308138.0,
127,60318,3,3,,103168744,5253,Unspecified,,,,,Percent change in Effective refractory period after intravenous administration of 1 mg/kg in Anesthetized Dogs,Other,2308138.0,
128,60319,3,3,,103168744,5253,Unspecified,,,,,Percent change in Effective refractory period after intravenous administration of 3 mg/kg in Anesthetized Dogs,Other,2308138.0,
129,60359,3,3,,103168744,5253,Unspecified,,,,,Efficacy in blocking sustained ventricular tachycardia (rate>250 bpm) elicited by programmed electrical stimulation in anesthetized dogs after iv administration of dose 1 mg/kg; no. of successful exp / total no. of exp = 2/7,Other,3572962.0,
130,60460,3,3,,103168744,5253,Unspecified,,,,,In vivo coronary flow in anesthetized dog at 30 mg/kg,Other,2319556.0,
131,60493,3,3,,103168744,5253,Unspecified,,,,,Efficacy in blocking sustained ventricular tachycardia (rate>250 bpm) elicited by programmed electrical stimulation in conscious dogs after iv administration of dose 3 mg/kg; no. of successful exp / total no. of exp = 4/4,Other,3572962.0,
132,60841,3,3,,103168744,5253,Unspecified,,,,,The compound was evaluated the change in functional refractory period at 10 mg/kg active dose,Other,3681900.0,
133,60918,3,3,,103168744,5253,Unspecified,,,,,Percent change in QTc interval after intravenous administration of 0.3 mg/kg in Anesthetized Dogs,Other,2308138.0,
134,60919,3,3,,103168744,5253,Unspecified,,,,,Percent change in QTc interval after intravenous administration of 1 mg/kg in Anesthetized Dogs,Other,2308138.0,
135,60920,3,3,,103168744,5253,Unspecified,,,,,Percent change in QTc interval after intravenous administration of 3 mg/kg in Anesthetized Dogs,Other,2308138.0,
136,61707,3,3,,103168744,5253,Unspecified,,,,,In vivo isoproterenol response in conscious dogs at 0.3 mg/kg,Other,2319556.0,
137,61708,3,3,,103168744,5253,Unspecified,,,,,In vivo isoproterenol response in conscious dogs at 1.0 mg/kg,Other,2319556.0,
138,61710,3,3,,103168744,5253,Unspecified,,,,,In vivo isoproterenol response in conscious dogs at 3.0 mg/kg,Other,2319556.0,
139,62096,3,4,,103168744,5253,Unspecified,,,,,Percent change in Mean Blood pressure after intravenous administration of 0.3 mg/kg in Anesthetized Dogs,Other,2308138.0,
140,62097,3,4,,103168744,5253,Unspecified,,,,,Percent change in Mean Blood pressure after intravenous administration of 1 mg/kg in Anesthetized Dogs,Other,2308138.0,
141,62098,3,4,,103168744,5253,Unspecified,,,,,Percent change in Mean Blood pressure after intravenous administration of 3 mg/kg in Anesthetized Dogs,Other,2308138.0,
142,62369,3,3,,103168744,5253,Unspecified,,,,,Compound was evaluated for Total peripheral resistance in dog,Other,1347318.0,
143,62370,3,3,,103168744,5253,Unspecified,,,,,In vivo total peripheral resistance in anesthetized dog at 30 mg/kg,Other,2319556.0,
144,62938,3,5,,103168744,5253,Unspecified,,,,,"Ventricular conduction time by the compound in open chest anesthetized dog, after iv administration at a dose of 10.0 mg/kg.",Other,1956040.0,
145,62939,3,5,,103168744,5253,Unspecified,,,,,"Ventricular conduction time by the compound in open chest anesthetized dog, after iv administration at a dose of 2.5 mg/kg.",Other,1956040.0,
146,62940,3,5,,103168744,5253,Unspecified,,,,,"Ventricular conduction time by the compound in open chest anesthetized dog, after iv administration at a dose of 5.0 mg/kg.",Other,1956040.0,
147,62968,3,5,,103168744,5253,Unspecified,,,,,"Ventricular effective refractory period by the compound in open chest anesthetized dog, after iv administration at a dose of 10.0 mg/kg.",Other,1956040.0,
148,62969,3,5,,103168744,5253,Unspecified,,,,,"Ventricular effective refractory period by the compound in open chest anesthetized dog, after iv administration at a dose of 2.5 mg/kg.",Other,1956040.0,
149,62970,3,5,,103168744,5253,Unspecified,,,,,"Ventricular effective refractory period by the compound in open chest anesthetized dog, after iv administration at a dose of 5.0 mg/kg.",Other,1956040.0,
150,63421,3,5,,103168744,5253,Unspecified,,,,,"Maximum rate of rise of the upstroke of transmembrane potential, in canine Purkinje Fibers at a concentration of 300 uM at 1000 ms (simulating normal heart rate)",Other,1956040.0,
151,63422,3,5,,103168744,5253,Unspecified,,,,,"Maximum rate of rise of the upstroke of transmembrane potential, in canine Purkinje Fibers at a concentration of 300 uM at 300 ms (simulating tachycardia)",Other,1956040.0,
152,63423,3,5,,103168744,5253,Unspecified,,,,,"Maximum rate of rise of the upstroke of transmembrane potential, in canine Purkinje Fibers at a concentration of 30 uM at 1000 ms (simulating normal heart rate)",Other,1956040.0,
153,63424,3,5,,103168744,5253,Unspecified,,,,,"Maximum rate of rise of the upstroke of transmembrane potential, in canine Purkinje Fibers at a concentration of 30 uM at 300 ms (simulating tachycardia)",Other,1956040.0,
154,63480,3,3,,103168744,5253,Unspecified,,,,,Percent change in FRP from control at active dose 10-30 mg/kg administered intraperitoneally in anesthetized dogs,Other,1976812.0,
155,63482,3,4,,103168744,5253,Unspecified,,,,,Percent change in blood pressure (BP) from control at active dose 10-30 mg/kg administered intraperitoneally in anesthetized dogs,Other,1976812.0,
156,63484,3,4,,103168744,5253,Unspecified,,,,,Percent change in heart rate (HR) from control at active dose 10-30 mg/kg administered intraperitoneally,Other,1976812.0,
157,63502,7,1,,103168744,5253,Active,,,,,Concentration that causes a 20% increase in APD95 (action potential duration at 95% repolarization) from control value in anesthetized dogs,Other,1976812.0,
158,63506,9,1,,103168744,5253,Unspecified,,,,,Concentration at which maximum change in APA95 was observed from control value in anesthetized dogs; The maximum observed change APD95 from control value and concentration at 100 uM when this occurred,Other,1976812.0,
159,71923,7,1,,103168744,5253,Active,,,,,Dose required to produce 20% increase in effective refractory period in male ferret.,Other,11133100.0,
160,72554,3,3,,103168744,5253,Unspecified,,,,,"Peak isometric tension during the basic stimulus trains (S1) during control and compound induced tension, expressed as percent control.",Other,11133100.0,
161,72563,3,4,,103168744,5253,Unspecified,,,,,In vitro contractile function in isolated ferret papillary muscle at 10 uM,Other,2319556.0,
162,74038,4,3,,103168744,5253,Unspecified,,,,,Effective dose in vivo for cardiac refractoriness (ERP) using paced guinea pig model,Other,8230126.0,
163,74044,3,3,,103168744,5253,Unspecified,,,,,Concentration required to prolong the effective refractory period (ERP) by 25% in isolated guinea pig left atria,Other,2319561.0,
164,75197,7,1,,103168744,5253,Active,,,,,Concentration (1-100 uM) that causes 10% prolongation in the action potential duration at 90% polarization in Guinea pig right ventricular papillary muscles,Other,2308138.0,
165,75205,3,3,,103168744,5253,Unspecified,,,,,The degree of cardiac depression produced by a concentration of 10 E-4 M was determined in guinea pig,Other,2319561.0,
166,75633,3,3,,103168744,5253,Unspecified,,,,,"Compound was evaluated for the increase in duration or cardiac APD (action potential duration) at 90% repolarization, using isolated guinea pig ventricular myocytes at concentration of 10000 nM",Other,2033581.0,
167,75643,3,3,,103168744,5253,Unspecified,,,,,"Compound was evaluated for the increase in duration or cardiac APD (action potential duration) at 90% repolarization, using isolated guinea pig ventricular myocytes at concentration of 50000 nM",Other,2033581.0,
168,76509,3,4,,103168744,5253,Unspecified,,,,,Maximum percent increase in 90% repolarization at a concentration of 100 uM in Guinea pig right ventricular papillary muscles,Other,2308138.0,
169,77823,5,3,,103168744,5253,Inactive,,,,,The maximum percent change in the maximum rate rise of the action Potential in Guinea pig right ventricular papillary muscles at concentration 1-100 uM; NS=Not significant,Other,2308138.0,
170,78122,4,3,,103168744,5253,Unspecified,,,,,In vivo index of cardiac contractility using paced guinea pig model,Other,8230126.0,
171,89649,6,3,,103168744,5253,Active,,,1.0,IC50,In vitro inhibition of Rb efflux in human T-cells; 1-10,Confirmatory,,
172,91481,4,7,,103168744,5253,Unspecified,,,,,Binding constant against human serum albumin (HSA),Other,11728183.0,
173,161144,4,6,,103168744,5253,Unspecified,,,,,"Percentage inhibition of specific binding of [3H]dofetilide (UK-68,798) from cardiac myocytes with blockade of delayed rectifier K+ channel",Other,8230126.0,
174,176310,5,8,,103168744,5253,Inconclusive,114754.0,24925.0,,,Beta-adrenoceptor blocking potency was estimated in vivo by blockade of the isoproterenol tachycardia response in rat; ND means no data,Other,6102152.0,
175,176310,5,8,,103168744,5253,Inconclusive,114768.0,24176.0,,,Beta-adrenoceptor blocking potency was estimated in vivo by blockade of the isoproterenol tachycardia response in rat; ND means no data,Other,6102152.0,
176,176310,5,8,,103168744,5253,Inconclusive,543882.0,25645.0,,,Beta-adrenoceptor blocking potency was estimated in vivo by blockade of the isoproterenol tachycardia response in rat; ND means no data,Other,6102152.0,
177,205269,3,7,,103168744,5253,Unspecified,,,,,Inhibition of binding of Batrachotoxinin [3H]BTX-B to high-affinity sites on voltage-dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 100 uM,Other,2579237.0,
178,205279,4,10,,103168744,5253,Unspecified,116452.0,25665.0,,,Percentage inhibition of specific binding of [3H]batrachotoxin [3H]BTX) in sodium channel from cardiac myocytes at 10 uM,Other,8230126.0,
179,211858,5,3,,103168744,5253,Inconclusive,,,,,Compound was tested for its toxicity after intravenous administration to mice in experiment 1; No data,Other,,
180,211860,5,3,,103168744,5253,Inconclusive,,,,,Compound was tested for its toxicity after intravenous administration to mice in experiment 2; No data,Other,,
181,211863,6,3,,103168744,5253,Unspecified,,,,,Compound was tested for its toxicity after oral administration to mice in experiment 1,Other,,
182,211865,6,3,,103168744,5253,Unspecified,,,,,Compound was tested for its toxicity after oral administration to mice in experiment 2,Other,,
183,215614,3,3,,103168744,5253,Unspecified,,,,,Dissociation constant against a series of agonists of membranes of the turkey erythrocyte containing mainly beta-adrenoceptors was determined.,Other,7154001.0,
184,218636,3,3,,103168744,5253,Unspecified,,,,,Percent change in FRP from control at active dose 0.3-10 mg/kg administered intraperitoneally,Other,1976812.0,
185,218750,3,4,,103168744,5253,Unspecified,,,,,Percent change in blood pressure (BP) from control at active dose 0.3-10 mg/kg administered intraperitoneally in anesthetized dogs,Other,1976812.0,
186,218752,3,4,,103168744,5253,Unspecified,,,,,Percent change in heart rate (HR) from control at active dose 0.3-10 mg/kg administered intraperitoneally in anesthetized dogs,Other,1976812.0,
187,218845,3,7,,103168744,5253,Unspecified,,,,,Change in Gibb's free energy at Low affinity beta-2-adrenoceptor in the membranes of bovine skeletal muscle preparation,Other,2836587.0,
188,218848,4,6,,103168744,5253,Unspecified,,,,,Change in Gibb's free energy at Low affinity beta-2-adrenoceptor in the Chang living cells,Other,2836587.0,
189,218875,7,1,,103168744,5253,Active,,,,,In vitro activity in isolated canine cardiac ventricular muscle tissue given as 20 percent increase or decrease in FRP (functional refractory period),Other,3681900.0,
190,218878,4,4,,103168744,5253,Unspecified,,,,,In vitro electrophysiological activity in isolated canine cardiac ventricular muscle tissue given as maximum change in FRP from control value at 100 uM concentration,Other,3681900.0,
191,220494,3,4,,103168744,5253,Unspecified,,,,,In vitro activity in isolated canine cardiac Purkinje fibers given as maximum change in APD95 from control value at 100 uM of concentration,Other,3681900.0,
192,220496,7,1,,103168744,5253,Active,,,,,In vitro activity in isolated canine cardiac Purkinje fibers given as 20 percent increase or decrease in action potential duration,Other,3681900.0,
193,229873,3,4,,103168744,5253,Unspecified,,,,,Ratio of number of active animals to number of treated at dose 0.3-10 mg/kg administered intraperitoneally in PES model in anesthetized dogs; 7/9,Other,1976812.0,
194,230079,3,4,,103168744,5253,Unspecified,,,,,Ratio of number of active animals to number of treated at dose 10-30 mg/kg administered intraperitoneally in anesthetized dogs; No of animals tested=7,Other,1976812.0,
195,233479,3,5,,103168744,5253,Unspecified,,,,,Ratio of number of active animals to number of treated at dose 0.3 mg/kg administered intraperitoneally in Epinephrine-induced model in anesthetized dogs; 6/6,Other,1976812.0,
196,233480,3,5,,103168744,5253,Unspecified,,,,,Ratio of number of active animals to number of treated at dose 1.0 mg/kg administered intraperitoneally in Epinephrine-induced model in anesthetized dogs; 4/4,Other,1976812.0,
197,239780,3,9,,103168744,5253,Unspecified,113576.0,213.0,,,Percentage plasma protein binding towards human serum albumin,Other,15801837.0,
198,243230,4,1,,103168744,5253,Unspecified,113576.0,213.0,354813000.0,Ki,Binding affinity towards human serum albumin,Confirmatory,15801837.0,
199,386623,4,8,,103168744,5253,Unspecified,313104181.0,6580.0,,,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy,Other,18788725.0,
200,392048,12,1,,103168744,5253,Unspecified,,,,EC50,Cardiotoxicity in iv dosed Dunkin-Hartley guinea pig assessed as drug level required to evoke 50 ms QTc prolongation administered as 3 fold cumulative doses measured every 10 seconds at end of every 20 mins follow up period of individual dose by ECG,Confirmatory,18262683.0,
201,392049,3,4,,103168744,5253,Unspecified,,,,,"Cardiotoxicity in Dunkin-Hartley guinea pig assessed as maximal QTc prolongation time at 10 mg/kg, iv administered as 3 fold cumulative doses measured every 10 seconds at end of every 20 mins follow up period of individual dose by ECG",Other,18262683.0,
202,404304,3,10,,103168744,5253,Unspecified,308153583.0,1244.0,,,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,Other,18457386.0,
203,414885,3,5,,103168744,5253,Unspecified,,,,,Electrophysiological effect in New Zealand rabbit right ventricular papillary muscle assessed as resting membrane potential at 20 um at 1 Hz stimulation frequency,Other,19309156.0,
204,414886,3,5,,103168744,5253,Unspecified,,,,,Electrophysiological effect in New Zealand rabbit right ventricular papillary muscle assessed as action potential amplitude at 20 uM at 1 Hz stimulation frequency,Other,19309156.0,
205,414887,3,5,,103168744,5253,Unspecified,,,,,Electrophysiological effect in New Zealand rabbit right ventricular papillary muscle assessed as action potential duration measured at 50% repolarization at 20 uM at 1 Hz stimulation frequency,Other,19309156.0,
206,414888,3,5,,103168744,5253,Unspecified,,,,,Electrophysiological effect in New Zealand rabbit right ventricular papillary muscle assessed as action potential duration measured at 90% repolarization at 20 uM at 1 Hz stimulation frequency,Other,19309156.0,
207,414890,6,1,,103168744,5253,Unspecified,,,,,Electrophysiological effect in New Zealand rabbit right ventricular papillary muscle assessed as maximal rate of depolarization at 20 uM at 1 Hz stimulation frequency,Other,19309156.0,
208,425652,7,2,,103168744,5253,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
209,425653,7,2,,103168744,5253,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
210,434959,1,1,,85788914,5253,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
211,444050,7,1,,103168744,5253,Unspecified,,,,,Fraction unbound in human plasma,Other,20070106.0,
212,444051,6,2,,103168744,5253,Unspecified,,,,,Total clearance in human,Other,20070106.0,
213,444052,6,2,,103168744,5253,Unspecified,,,,,Hepatic clearance in human,Other,20070106.0,
214,444053,6,2,,103168744,5253,Unspecified,,,,,Renal clearance in human,Other,20070106.0,
215,444054,6,1,,103168744,5253,Unspecified,,,,,Oral bioavailability in human,Other,20070106.0,
216,444055,3,3,,103168744,5253,Unspecified,,,,,Fraction absorbed in human,Other,20070106.0,
217,444056,3,3,,103168744,5253,Unspecified,,,,,Fraction escaping gut-wall elimination in human,Other,20070106.0,
218,444057,3,3,,103168744,5253,Unspecified,,,,,Fraction escaping hepatic elimination in human,Other,20070106.0,
219,444058,6,2,,103168744,5253,Unspecified,,,,,Volume of distribution at steady state in human,Other,20070106.0,
220,463106,1,2,,90341280,5253,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
221,476929,3,3,,103168744,5253,Unspecified,,,,,Human intestinal absorption in po dosed human,Other,20022146.0,
222,481439,3,4,,103168744,5253,Unspecified,,,,,Absolute bioavailability in human,Other,20373811.0,
223,481442,3,6,,103168744,5253,Unspecified,,,,,Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells,Other,20373811.0,
224,485290,1,1,,26751989,5253,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
225,485295,1,2,,90341280,5253,Inactive,30027657.0,,,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
226,485297,1,1,,90341280,5253,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
227,485298,1,1,,90341280,5253,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
228,485313,1,2,,90341280,5253,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
229,485342,1,2,,90341280,5253,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
230,485345,1,2,,90341280,5253,Inactive,,,,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
231,485366,1,2,,90341280,5253,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
232,485368,1,2,,90341280,5253,Inconclusive,72386991.0,3656265.0,37.933,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
233,488772,1,1,,90341280,5253,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
234,488773,1,2,,90341280,5253,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
235,488816,1,1,,90341280,5253,Inactive,4758356.0,2237.0,,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
236,488837,1,1,,90341280,5253,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
237,488949,1,2,,90341280,5253,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
238,488953,1,1,,90341280,5253,Inactive,187960037.0,10951.0,,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
239,488978,1,1,,90341280,5253,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
240,488981,1,1,,90341280,5253,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
241,488982,1,1,,90341280,5253,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
242,488983,1,1,,90341280,5253,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
243,493106,1,1,,90341280,5253,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
244,493107,1,1,,90341280,5253,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
245,493153,1,1,,90341280,5253,Inactive,,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
246,493153,1,1,,90341280,5253,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
247,493164,1,2,,90341280,5253,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
248,493164,1,2,,90341280,5253,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
249,493164,1,2,,90341280,5253,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
250,504327,1,1,,90341280,5253,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
251,504332,1,1,,90341280,5253,Inactive,168985070.0,,0.7519,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
252,504536,1,1,,90341280,5253,Inactive,5453898.0,5300.0,,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
253,504547,1,1,,90341280,5253,Inactive,115503961.0,4357161.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
254,504548,1,2,,90341280,5253,Inactive,157877932.0,5655980.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
255,504749,1,3,,26751989,5253,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
256,504749,1,3,,104171235,5253,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
257,504749,1,3,1.0,26751989,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
258,504749,1,3,2.0,104171235,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
259,504749,1,3,3.0,104171235,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
260,504749,1,3,4.0,26751989,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
261,504749,1,3,5.0,104171235,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
262,504749,1,3,6.0,26751989,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
263,504749,1,3,7.0,26751989,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
264,504749,1,3,8.0,26751989,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
265,504749,1,3,9.0,104171235,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
266,504749,1,3,10.0,26751989,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
267,504749,1,3,11.0,26751989,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
268,504749,1,3,12.0,104171235,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
269,504749,1,3,13.0,26751989,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
270,504749,1,3,14.0,104171235,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
271,504749,1,3,15.0,26751989,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
272,504749,1,3,16.0,26751989,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
273,504749,1,3,17.0,26751989,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
274,504749,1,3,18.0,26751989,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
275,504749,1,3,19.0,26751989,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
276,504749,1,3,20.0,104171235,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
277,504749,1,3,21.0,26751989,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
278,504749,1,3,22.0,104171235,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
279,504749,1,3,23.0,104171235,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
280,504749,1,3,24.0,26751989,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
281,504749,1,3,25.0,26751989,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
282,504749,1,3,26.0,26751989,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
283,504749,1,3,27.0,104171235,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
284,504749,1,3,28.0,104171235,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
285,504749,1,3,29.0,26751989,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
286,504749,1,3,30.0,104171235,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
287,504749,1,3,31.0,104171235,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
288,504749,1,3,32.0,26751989,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
289,504749,1,3,33.0,104171235,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
290,504749,1,3,34.0,26751989,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
291,504749,1,3,35.0,26751989,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
292,504749,1,3,36.0,104171235,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
293,504749,1,3,37.0,26751989,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
294,504749,1,3,38.0,104171235,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
295,504749,1,3,39.0,26751989,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
296,504749,1,3,40.0,26751989,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
297,504749,1,3,41.0,104171235,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
298,504749,1,3,42.0,26751989,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
299,504749,1,3,43.0,26751989,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
300,504749,1,3,44.0,26751989,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
301,504749,1,3,45.0,104171235,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
302,504749,1,3,46.0,26751989,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
303,504749,1,3,47.0,26751989,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
304,504749,1,3,48.0,26751989,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
305,504749,1,3,49.0,26751989,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
306,504749,1,3,50.0,104171235,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
307,504749,1,3,51.0,26751989,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
308,504749,1,3,52.0,26751989,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
309,504749,1,3,53.0,104171235,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
310,504749,1,3,54.0,26751989,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
311,504749,1,3,55.0,104171235,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
312,504749,1,3,56.0,26751989,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
313,504749,1,3,57.0,26751989,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
314,504749,1,3,58.0,26751989,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
315,504749,1,3,59.0,104171235,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
316,504749,1,3,60.0,104171235,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
317,504749,1,3,61.0,26751989,5253,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
318,504810,1,2,,90341280,5253,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
319,504812,1,2,,90341280,5253,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
320,504832,1,1,,104171235,5253,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
321,504834,1,1,,104171235,5253,Inconclusive,,,16.9441,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
322,504836,1,2,,90341280,5253,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
323,504845,1,1,,90341280,5253,Inactive,86301163.0,5999.0,0.0844,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
324,504845,1,1,,104171235,5253,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
325,504847,1,1,,90341280,5253,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
326,504847,1,1,,104171235,5253,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
327,504865,1,1,,90341280,5253,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
328,504865,1,1,,104171235,5253,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
329,540209,4,3,,103168744,5253,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
330,540210,4,3,,103168744,5253,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
331,540211,2,5,,103168744,5253,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
332,540212,4,3,,103168744,5253,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
333,540213,4,3,,103168744,5253,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
334,540234,2,5,,103168744,5253,Unspecified,,,,,Cerep Phospholipidosis assay (HepG2 cells),Other,,
335,540256,1,2,,90341280,5253,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
336,540276,1,2,,26751989,5253,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
337,540276,1,2,,50104666,5253,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
338,540276,1,2,,90341280,5253,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
339,540276,1,2,,104171235,5253,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
340,567091,2,6,,103168744,5253,Unspecified,,,,,Drug absorption in human assessed as human intestinal absorption rate,Other,21112128.0,
341,588208,2,3,,103168744,5253,Unspecified,,,,,Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset,Other,20799726.0,
342,588211,2,3,,103168744,5253,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
343,588212,2,3,,103168744,5253,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
344,588213,2,3,,103168744,5253,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
345,588214,2,3,,103168744,5253,Unspecified,,,,,"FDA HLAED, liver enzyme composite activity",Other,16472241.0,
346,588215,2,3,,103168744,5253,Unspecified,,,,,"FDA HLAED, alkaline phosphatase increase",Other,16472241.0,
347,588216,2,3,,103168744,5253,Unspecified,,,,,"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase",Other,16472241.0,
348,588217,2,3,,103168744,5253,Unspecified,,,,,"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase",Other,16472241.0,
349,588218,2,3,,103168744,5253,Unspecified,,,,,"FDA HLAED, lactate dehydrogenase (LDH) increase",Other,16472241.0,
350,588219,2,3,,103168744,5253,Unspecified,,,,,"FDA HLAED, gamma-glutamyl transferase (GGT) increase",Other,16472241.0,
351,588220,2,3,,103168744,5253,Unspecified,,,,,Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset,Other,20020916.0,
352,588349,1,1,,90341280,5253,Inactive,,,,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
353,588378,1,1,,90341280,5253,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
354,588453,1,1,,90341280,5253,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
355,588456,1,1,,90341280,5253,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
356,588579,1,1,,90341280,5253,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
357,588579,1,1,,104171235,5253,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
358,588795,1,1,,90341280,5253,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
359,588834,2,1,,26751989,5253,Active,325651834.0,3757.0,4.4668,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
360,592681,1,4,,103168744,5253,Unspecified,,,,,Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis,Other,21458999.0,
361,602332,1,1,,90341280,5253,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
362,602332,1,1,,104171235,5253,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
363,624030,1,2,,104171235,5253,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
364,624031,1,2,,104171235,5253,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
365,624032,1,2,,104171235,5253,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
366,624044,1,2,,104171235,5253,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
367,624101,1,2,,85788914,5253,Inactive,62203298.0,3417.0,,,Development of  IDH1/2 inhibitors (CTD2project) Measured in Biochemical System Using Plate Reader - 2107-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
368,624146,1,1,,90341280,5253,Inactive,71051501.0,2744.0,12.5893,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
369,624147,1,1,,90341280,5253,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
370,624148,1,2,,90341280,5253,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
371,624149,1,1,,90341280,5253,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
372,624151,1,1,,85788914,5253,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Re-Activators of the P53 Mutant Pathway Measured in Cell-Based System Using Plate Reader - 2071-01_Activator_SinglePoint_HTS_Activity,Screening,,
373,624156,1,1,,85788914,5253,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
374,624170,1,1,,104171235,5253,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
375,624172,1,1,,104171235,5253,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
376,624173,1,3,,104171235,5253,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
377,624296,1,1,,26751989,5253,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
378,624296,1,1,,104171235,5253,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
379,624297,1,1,,26751989,5253,Inconclusive,7705682.0,51053.0,12.4362,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
380,624297,1,1,,104171235,5253,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
381,624349,1,2,,92308885,5253,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
382,624455,1,1,,90341280,5253,Inactive,299681.0,1812.0,,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
383,625144,5,5,,103168744,5253,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
384,625145,4,7,,103168744,5253,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
385,625146,5,5,,103168744,5253,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
386,625147,4,7,,103168744,5253,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
387,625148,4,7,,103168744,5253,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
388,625149,4,7,,103168744,5253,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
389,625150,5,5,,103168744,5253,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
390,625151,4,7,,103168744,5253,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
391,625152,4,7,,103168744,5253,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
392,625153,4,7,,103168744,5253,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
393,625154,4,7,,103168744,5253,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
394,625155,4,7,,103168744,5253,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
395,625156,1,9,,103168744,5253,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
396,625157,6,2,,103168744,5253,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
397,625158,3,4,,103168744,5253,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
398,625159,5,5,,103168744,5253,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
399,625160,1,9,,103168744,5253,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
400,625161,4,7,,103168744,5253,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
401,625162,4,7,,103168744,5253,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
402,625163,4,7,,103168744,5253,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
403,625164,1,6,,103168744,5253,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
404,625165,3,4,,103168744,5253,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
405,625166,3,4,,103168744,5253,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
406,625167,5,5,,103168744,5253,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
407,625168,4,7,,103168744,5253,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
408,625169,1,6,,103168744,5253,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
409,625170,3,4,,103168744,5253,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
410,625171,4,7,,103168744,5253,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
411,625172,4,7,,103168744,5253,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
412,625173,5,5,,103168744,5253,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
413,625174,5,5,,103168744,5253,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
414,625175,5,5,,103168744,5253,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
415,625176,1,9,,103168744,5253,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
416,625177,5,5,,103168744,5253,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
417,625178,5,5,,103168744,5253,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
418,625179,1,9,,103168744,5253,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
419,625180,5,5,,103168744,5253,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
420,625181,5,5,,103168744,5253,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
421,625182,5,5,,103168744,5253,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
422,625183,5,5,,103168744,5253,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
423,625184,5,5,,103168744,5253,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
424,625185,5,5,,103168744,5253,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
425,625186,5,5,,103168744,5253,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
426,625187,5,5,,103168744,5253,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
427,625188,1,9,,103168744,5253,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
428,625189,1,7,,103168744,5253,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
429,625190,4,5,,103168744,5253,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
430,625191,4,7,,103168744,5253,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
431,625192,4,7,,103168744,5253,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
432,625193,5,5,,103168744,5253,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
433,625194,4,7,,103168744,5253,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
434,625195,4,7,,103168744,5253,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
435,625196,5,6,,103168744,5253,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
436,625197,3,4,,103168744,5253,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
437,625198,4,7,,103168744,5253,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
438,625199,4,7,,103168744,5253,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
439,625200,4,7,,103168744,5253,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
440,625201,4,7,,103168744,5253,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
441,625202,4,7,,103168744,5253,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
442,625203,4,7,,103168744,5253,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
443,625204,4,7,,103168744,5253,Active,48429211.0,153.0,1.4434,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
444,625205,4,7,,103168744,5253,Active,296439450.0,154.0,0.4339,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
445,625206,4,7,,103168744,5253,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
446,625207,4,7,,103168744,5253,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
447,625208,5,5,,103168744,5253,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
448,625209,4,7,,103168744,5253,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
449,625210,3,4,,103168744,5253,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
450,625211,1,6,,103168744,5253,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
451,625212,3,4,,103168744,5253,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
452,625213,4,7,,103168744,5253,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
453,625214,1,9,,103168744,5253,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
454,625215,3,4,,103168744,5253,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
455,625216,3,4,,103168744,5253,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
456,625217,4,7,,103168744,5253,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
457,625218,4,7,,103168744,5253,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
458,625219,3,4,,103168744,5253,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
459,625220,4,7,,103168744,5253,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
460,625221,4,7,,103168744,5253,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
461,625222,4,7,,103168744,5253,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
462,625223,4,7,,103168744,5253,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
463,625224,3,4,,103168744,5253,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
464,625225,3,4,,103168744,5253,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
465,625226,4,7,,103168744,5253,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
466,625227,4,7,,103168744,5253,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
467,625228,4,7,,103168744,5253,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
468,625229,5,5,,103168744,5253,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
469,625230,1,6,,103168744,5253,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
470,625231,4,7,,103168744,5253,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
471,625232,1,9,,103168744,5253,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
472,625233,4,7,,103168744,5253,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
473,625234,3,4,,103168744,5253,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
474,625235,4,7,,103168744,5253,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
475,625236,5,5,,103168744,5253,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
476,625237,4,7,,103168744,5253,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
477,625238,4,7,,103168744,5253,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
478,625239,4,7,,103168744,5253,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
479,625240,1,9,,103168744,5253,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
480,625241,4,7,,103168744,5253,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
481,625242,4,7,,103168744,5253,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
482,625243,5,5,,103168744,5253,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
483,625244,5,5,,103168744,5253,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
484,625245,5,5,,103168744,5253,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
485,625246,1,9,,103168744,5253,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
486,625247,5,5,,103168744,5253,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
487,625248,5,5,,103168744,5253,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
488,625249,5,5,,103168744,5253,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
489,625250,5,5,,103168744,5253,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
490,625251,5,5,,103168744,5253,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
491,625252,4,7,,103168744,5253,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
492,625253,4,7,,103168744,5253,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
493,625254,4,7,,103168744,5253,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
494,625255,4,7,,103168744,5253,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
495,625256,4,7,,103168744,5253,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
496,625257,4,7,,103168744,5253,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
497,625258,4,7,,103168744,5253,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
498,625259,4,7,,103168744,5253,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
499,625260,3,4,,103168744,5253,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
500,625261,3,4,,103168744,5253,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
501,625262,3,4,,103168744,5253,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
502,625263,4,7,,103168744,5253,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
503,625264,3,4,,103168744,5253,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
504,625265,1,6,,103168744,5253,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
505,625266,3,4,,103168744,5253,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
506,625267,3,4,,103168744,5253,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
507,625268,4,2,,103168744,5253,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
508,625268,4,2,,103168744,5253,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
509,625268,4,2,,103168744,5253,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
510,625268,4,2,,103168744,5253,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
511,625269,4,7,,103168744,5253,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
512,625270,4,7,,103168744,5253,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
513,625271,5,5,,103168744,5253,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
514,625272,3,4,,103168744,5253,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
515,625273,4,6,,103168744,5253,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
516,625274,1,6,,103168744,5253,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
517,625275,3,4,,103168744,5253,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
518,625279,1,3,,103168744,5253,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
519,625280,1,3,,103168744,5253,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
520,625281,1,3,,103168744,5253,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
521,625282,1,3,,103168744,5253,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
522,625283,1,3,,103168744,5253,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
523,625284,1,3,,103168744,5253,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
524,625285,1,3,,103168744,5253,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
525,625286,1,3,,103168744,5253,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
526,625287,1,3,,103168744,5253,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
527,625288,1,3,,103168744,5253,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
528,625289,1,3,,103168744,5253,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
529,625290,1,3,,103168744,5253,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
530,625291,1,3,,103168744,5253,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
531,625292,1,3,,103168744,5253,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
532,651631,4,1,,144203812,5253,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
533,651632,4,1,,144203812,5253,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
534,651633,4,1,,144203812,5253,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
535,651634,4,1,,144203812,5253,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
536,651635,1,3,,90341280,5253,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
537,651828,1,2,,92308885,5253,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
538,652048,1,2,,144203812,5253,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
539,652051,1,1,,144203812,5253,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
540,652106,1,1,,90341280,5253,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
541,678712,1,8,,103168744,5253,Active,117144.0,1544.0,,,Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins,Other,22931300.0,
542,678713,1,8,,103168744,5253,Active,6686268.0,1559.0,,,Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,Other,22931300.0,
543,678714,1,8,,103168744,5253,Active,60416369.0,1557.0,,,Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
544,678715,1,8,,103168744,5253,Active,84028191.0,1565.0,,,Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
545,678716,1,8,,103168744,5253,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins,Other,22931300.0,
546,678717,1,8,,103168744,5253,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins,Other,22931300.0,
547,678721,1,5,,103168744,5253,Active,,,,,Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis,Other,22931300.0,
548,678722,1,5,,103168744,5253,Inconclusive,,,,,Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH,Other,22931300.0,
549,686977,2,1,,49699392,5253,Inactive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
550,686978,1,1,,144203812,5253,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
551,686979,1,1,,144203812,5253,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
552,699539,1,7,,103168744,5253,Unspecified,12643959.0,10599.0,,,Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting,Other,22541068.0,
553,699540,1,7,,103168744,5253,Unspecified,27734563.0,28234.0,,,Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
554,699541,1,7,,103168744,5253,Unspecified,313104012.0,11309.0,,,Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
555,720516,2,1,,144203812,5253,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
556,720532,1,1,,144203812,5253,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
557,720533,1,1,,144203812,5253,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
558,720538,1,2,,90341280,5253,Inactive,220983390.0,410.0,5.3582,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
559,720552,2,1,,144203812,5253,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
560,720559,1,2,,90341280,5253,Inactive,112927.0,351.0,,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
561,720572,1,2,,90341280,5253,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
562,720573,1,2,,90341280,5253,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
563,720634,2,1,,144203812,5253,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
564,720635,2,1,,144203812,5253,Inconclusive,,,7.4978,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
565,720637,2,1,,144203812,5253,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
566,720641,1,2,,92308885,5253,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
567,720674,2,2,,144203812,5253,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
568,720675,2,2,,144203812,5253,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
569,720678,2,1,,144203812,5253,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
570,720679,2,1,,144203812,5253,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
571,720680,2,1,,144203812,5253,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
572,720681,2,1,,144203812,5253,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
573,720682,2,1,,144203812,5253,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
574,720683,2,1,,144203812,5253,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
575,720684,2,1,,144203812,5253,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
576,720685,2,1,,144203812,5253,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
577,720686,2,1,,144203812,5253,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
578,720687,2,2,,144203812,5253,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
579,720691,4,1,,144203812,5253,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
580,720692,3,1,,144203812,5253,Inconclusive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
581,720693,3,1,,144203812,5253,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
582,720717,1,3,,92308885,5253,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
583,720719,2,1,,144203812,5253,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
584,720725,2,1,,144203812,5253,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
585,743012,3,1,,144203812,5253,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
586,743014,3,1,,144203812,5253,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
587,743015,3,1,,144203812,5253,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
588,743033,3,1,,144203812,5253,Inconclusive,,,4.2527,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
589,743035,2,1,,144203812,5253,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
590,743036,2,1,,144203812,5253,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
591,743040,3,1,,144203812,5253,Active,124375976.0,367.0,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
592,743041,3,1,,144203812,5253,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
593,743042,3,1,,144203812,5253,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
594,743053,2,1,,144203812,5253,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
595,743054,2,1,,144203812,5253,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
596,743063,2,1,,144203812,5253,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
597,743064,3,1,,144203812,5253,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
598,743065,3,1,,144203812,5253,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
599,743066,3,1,,144203812,5253,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
600,743067,2,1,,144203812,5253,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
601,743069,2,1,,144203812,5253,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
602,743074,2,1,,144203812,5253,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
603,743075,2,1,,144203812,5253,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
604,743077,2,1,,144203812,5253,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
605,743078,2,1,,144203812,5253,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
606,743079,3,1,,144203812,5253,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
607,743080,3,1,,144203812,5253,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
608,743081,3,1,,144203812,5253,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
609,743083,3,1,,144203812,5253,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
610,743084,3,1,,144203812,5253,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
611,743085,3,1,,144203812,5253,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
612,743086,3,1,,144203812,5253,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
613,743091,2,1,,144203812,5253,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
614,743094,3,1,,144203812,5253,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
615,743122,2,1,,144203812,5253,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
616,743139,2,1,,144203812,5253,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
617,743140,2,1,,144203812,5253,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
618,743205,1,1,,90341280,5253,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
619,743205,1,1,,90341280,5253,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
620,743206,1,1,,90341280,5253,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
621,743206,1,1,,90341280,5253,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
622,743207,1,1,,90341280,5253,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
623,743207,1,1,,90341280,5253,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
624,743244,1,1,,90341280,5253,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
625,743244,1,1,,144203812,5253,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
626,743344,1,1,,104171235,5253,Inactive,,,8.4071,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
627,743345,1,1,,104171235,5253,Inactive,,,0.2369,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
628,743346,1,1,,104171235,5253,Inactive,,,5.3045,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
629,743347,1,1,,104171235,5253,Inactive,,,16.7744,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
630,781009,1,1,,103168744,5253,Unspecified,,,,,Apparent permeability of the compound in human Caco2 cells at 1 uM,Other,24113240.0,
631,781328,1,2,,103168744,5253,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by Luan ref: Pharm. Res. 2005,Other,24249037.0,
632,925609,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020422,Other,,
633,925610,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020422,Other,,
634,925611,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020422,Other,,
635,925612,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020422,Other,,
636,925613,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020422",Other,,
637,925614,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020422,Other,,
638,925615,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020422,Other,,
639,925616,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020422,Other,,
640,925617,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020422,Other,,
641,926245,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020422,Other,,
642,926246,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020422,Other,,
643,926247,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020422,Other,,
644,926248,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020422,Other,,
645,926249,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020422,Other,,
646,926250,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020422,Other,,
647,926251,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020422,Other,,
648,926252,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020422,Other,,
649,926253,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020422,Other,,
650,926254,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020422,Other,,
651,926255,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020422,Other,,
652,926256,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020422",Other,,
653,926257,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020422,Other,,
654,926258,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020422,Other,,
655,926259,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020422,Other,,
656,926260,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020422,Other,,
657,926261,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020422,Other,,
658,926262,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020422,Other,,
659,926263,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020422,Other,,
660,926264,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020422,Other,,
661,926265,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020422,Other,,
662,926266,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020422,Other,,
663,926267,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020422,Other,,
664,934256,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020422,Other,,
665,934257,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020422,Other,,
666,934258,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020422,Other,,
667,934259,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020422,Other,,
668,934260,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020422,Other,,
669,934261,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020422,Other,,
670,967273,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020422,Other,,
671,967274,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020422,Other,,
672,967275,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020422,Other,,
673,967276,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020422,Other,,
674,967277,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020422,Other,,
675,967278,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020422,Other,,
676,967279,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020422,Other,,
677,967280,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020422,Other,,
678,967281,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020422,Other,,
679,967282,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020422,Other,,
680,967283,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020422,Other,,
681,967284,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020422,Other,,
682,967285,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020422,Other,,
683,967286,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020422,Other,,
684,967287,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020422,Other,,
685,967288,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020422,Other,,
686,967289,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020422,Other,,
687,967290,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020422,Other,,
688,967936,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020422,Other,,
689,967937,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020422,Other,,
690,967938,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020422,Other,,
691,967939,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020422,Other,,
692,967940,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020422,Other,,
693,967941,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020422,Other,,
694,967942,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020422,Other,,
695,967943,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020422,Other,,
696,967944,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020422,Other,,
697,967945,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020422,Other,,
698,967946,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020422,Other,,
699,971330,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020422,Other,,
700,971331,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020422,Other,,
701,971332,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020422,Other,,
702,971333,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020422,Other,,
703,971334,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020422,Other,,
704,971335,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020422,Other,,
705,971336,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020422,Other,,
706,971337,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020422,Other,,
707,971338,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020422,Other,,
708,1008074,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: S020422",Other,,
709,1008075,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020422",Other,,
710,1008076,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020422",Other,,
711,1008077,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S020422",Other,,
712,1008078,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S020422",Other,,
713,1008079,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S020422",Other,,
714,1008080,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S020422",Other,,
715,1008081,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Fibrosis; Study_ID: S020422",Other,,
716,1008082,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Myocyte, Degeneration; Study_ID: S020422",Other,,
717,1008083,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020422",Other,,
718,1008084,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S020422,Other,,
719,1008085,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S020422",Other,,
720,1008086,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S020422,Other,,
721,1008087,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S020422",Other,,
722,1008088,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S020422",Other,,
723,1008089,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S020422",Other,,
724,1008090,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S020422",Other,,
725,1008091,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S020422",Other,,
726,1008092,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S020422",Other,,
727,1008093,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S020422",Other,,
728,1008094,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S020422",Other,,
729,1008095,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020422",Other,,
730,1008096,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: S020422",Other,,
731,1008097,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: S020422",Other,,
732,1008098,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020422",Other,,
733,1008684,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020422",Other,,
734,1008685,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S020422",Other,,
735,1008686,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S020422",Other,,
736,1008687,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020422",Other,,
737,1008688,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S020422",Other,,
738,1010552,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S020422",Other,,
739,1010553,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S020422",Other,,
740,1010554,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S020422",Other,,
741,1010555,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S020422",Other,,
742,1010556,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S020422",Other,,
743,1010557,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S020422",Other,,
744,1010558,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: S020422",Other,,
745,1010559,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Lipid Accumulation; Study_ID: S020422",Other,,
746,1010560,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: S020422",Other,,
747,1010561,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Edema; Study_ID: S020422",Other,,
748,1010562,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S020422,Other,,
749,1010563,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S020422,Other,,
750,1010564,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S020422",Other,,
751,1010565,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020422",Other,,
752,1010566,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020422",Other,,
753,1010567,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S020422",Other,,
754,1010568,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Fibrosis; Study_ID: S020422",Other,,
755,1010569,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mixed Cell; Study_ID: S020422",Other,,
756,1010570,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020422",Other,,
757,1010571,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Hyperplasia; Study_ID: S020422",Other,,
758,1010572,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020422",Other,,
759,1010573,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: S020422",Other,,
760,1010574,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Fibrosis; Study_ID: S020422",Other,,
761,1010575,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S020422,Other,,
762,1010576,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020422",Other,,
763,1010577,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S020422",Other,,
764,1010578,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S020422",Other,,
765,1010579,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S020422",Other,,
766,1010580,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S020422,Other,,
767,1011163,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020422",Other,,
768,1011164,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S020422",Other,,
769,1011165,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020422",Other,,
770,1011166,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Myocyte, Degeneration; Study_ID: S020422",Other,,
771,1011167,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020422",Other,,
772,1011168,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S020422",Other,,
773,1011169,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S020422",Other,,
774,1011170,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020422",Other,,
775,1011171,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S020422",Other,,
776,1011172,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S020422",Other,,
777,1011173,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020422",Other,,
778,1012267,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Endocardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020422",Other,,
779,1012268,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Tunica Media, Hypertrophy; Study_ID: S020422",Other,,
780,1012269,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S020422",Other,,
781,1012270,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S020422,Other,,
782,1012271,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S020422",Other,,
783,1012272,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S020422",Other,,
784,1012273,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S020422",Other,,
785,1012274,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Myocyte, Degeneration; Study_ID: S020422",Other,,
786,1012275,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: S020422",Other,,
787,1012276,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mixed Cell; Study_ID: S020422",Other,,
788,1012277,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Fibrosis; Study_ID: S020422",Other,,
789,1012278,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Myocyte, Degeneration; Study_ID: S020422",Other,,
790,1012279,1,3,,103168744,5253,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S020422,Other,,
791,1012280,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S020422",Other,,
792,1012281,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S020422",Other,,
793,1012282,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S020422",Other,,
794,1012283,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S020422",Other,,
795,1012284,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S020422",Other,,
796,1012285,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S020422",Other,,
797,1012286,1,3,,103168744,5253,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: S020422",Other,,
798,1079931,1,1,,103168744,5253,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
799,1079932,1,1,,103168744,5253,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
800,1079933,1,1,,103168744,5253,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
801,1079934,1,1,,103168744,5253,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
802,1079935,1,1,,103168744,5253,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
803,1079936,1,1,,103168744,5253,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
804,1079937,1,1,,103168744,5253,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
805,1079938,1,1,,103168744,5253,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
806,1079939,1,1,,103168744,5253,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
807,1079940,1,1,,103168744,5253,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
808,1079941,1,1,,103168744,5253,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
809,1079942,1,1,,103168744,5253,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
810,1079943,1,1,,103168744,5253,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
811,1079944,1,1,,103168744,5253,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
812,1079945,1,1,,103168744,5253,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
813,1079946,1,1,,103168744,5253,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
814,1079947,1,1,,103168744,5253,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
815,1079948,1,1,,103168744,5253,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
816,1079949,1,1,,103168744,5253,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
817,1097336,1,3,,103168744,5253,Unspecified,,,,,Drug level in Homo sapiens (human) whole blood assessed as retention time by UPLC-TOF-MS analysis,Other,,
818,1117301,1,2,,104171235,5253,Inactive,,,1.9953,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 blue channel",Confirmatory,,
819,1117302,1,2,,104171235,5253,Inactive,,,1.9953,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen1 green channel",Confirmatory,,
820,1117303,1,2,,104171235,5253,Inactive,,,1.42,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 ratio channel",Confirmatory,,
821,1117311,1,1,,104171235,5253,Inactive,,,1.9952599999999998,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, blue channel",Confirmatory,,
822,1117315,1,1,,104171235,5253,Inactive,,,1.9952599999999998,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, green channel",Confirmatory,,
823,1117318,1,1,,104171235,5253,Inactive,,,1.41254,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, ratio channel",Confirmatory,,
824,1135145,1,2,,103168744,5253,Active,,,0.15849000000000002,Kd,Antagonist activity at guinea pig atrial beta adrenergic receptor assessed as isometric contractions by force displacement transducer,Confirmatory,15112.0,
825,1135149,1,2,,103168744,5253,Unspecified,,,,,"Hypotensive activity at guinea pig assessed as decrease in blood pressure at 50 mg/kg, po after 1 hr (Rvb = 112 +/- 2.6 to 122 +/- 2.7 mmHg)",Other,15112.0,
826,1135150,1,2,,103168744,5253,Unspecified,,,,,"Hypotensive activity at guinea pig assessed as decrease in blood pressure at 50 mg/kg, po after 3 hrs (Rvb = 112 +/- 2.6 to 122 +/- 2.7 mmHg)",Other,15112.0,
827,1135151,1,2,,103168744,5253,Unspecified,,,,,"Hypotensive activity at guinea pig assessed as decrease in blood pressure at 50 mg/kg, po after 5 hrs (Rvb = 112 +/- 2.6 to 122 +/- 2.7 mmHg)",Other,15112.0,
828,1159580,2,1,,268738505,5253,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
829,1159607,2,1,,312309899,5253,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
830,1207703,1,2,,103168744,5253,Unspecified,308153651.0,775.0,1023.0,IC50,Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit,Confirmatory,22761000.0,
831,1207772,1,1,,103168744,5253,Unspecified,,,193.3,IC50,"Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits",Confirmatory,23812503.0,
832,1224824,1,1,,104171235,5253,Inactive,,,26.3506,Potency,High-throughput drug toxicity screening in the BPDCN cell line Gen2.2,Confirmatory,,
833,1224825,1,1,,104171235,5253,Inactive,,,,Potency,High-throughput drug toxicity screening in the BPDCN cell line Cal-1,Confirmatory,,
834,1224857,2,1,,104171235,5253,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
835,1224859,2,1,,90341280,5253,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
836,1224859,2,1,,104171235,5253,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
837,1224863,1,1,,176483982,5253,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
838,1224863,1,1,,176484839,5253,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
839,1224863,1,1,,316919512,5253,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
840,1224905,2,1,,92308885,5253,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
841,1224905,2,1,,92308885,5253,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
842,1259252,1,1,,104171235,5253,Active,169655958.0,,5.8992,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),Confirmatory,,
843,1259253,1,1,,104171235,5253,Active,169655958.0,,16.6261,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),Confirmatory,,
844,1259255,1,1,,104171235,5253,Active,169655958.0,,16.6261,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),Confirmatory,,
845,1259256,1,1,,104171235,5253,Inconclusive,169655958.0,,37.2212,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),Confirmatory,,
846,1259325,1,2,,336954619,5253,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
847,1259344,1,1,,144203812,5253,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
848,1259355,1,1,,26751989,5253,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
849,1259356,1,1,,104171235,5253,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
850,1259407,1,1,,363902154,5253,Inactive,,,,,CCRIS mutagenicity studies,Other,,
851,1259416,1,2,,340080576,5253,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
852,1259416,1,2,,375174720,5253,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
853,1259421,1,1,,340080576,5253,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
854,1259421,1,1,,375174720,5253,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
855,1259423,1,2,,354824155,5253,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
856,1259423,1,2,,354914288,5253,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
857,1259423,1,2,,354938617,5253,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
858,1259423,1,2,,354941211,5253,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
